Skip to main content
OpenTrials
Completed

NCT Number: NCT01362933

National Evaluation of the Adherence to Recommendations of Venous Thrombo Embolism Treatment in Cancer Patients

Treatment of venous thromboembolism in cancer patients is specific and has been validated in trials that favor the use of LMWH (Low Molecular Weight Heparin) instead of VKA (Vitamin K Antagonist) treatment during 6 months. International recommendations have diffused this option.It is necessary to evaluate the compliance of physicians to this treatment by measuring the number of patients with cancer treated with long term use of LMWH.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neoplasms Cardiovascular Diseases Embolism and Thrombosis Thromboembolism Vascular Diseases Venous Thromboembolism

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHR Annecy, Annecy, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All patients with cancer present in the clinic, hospital, out patients diagnosed with a VTE during the 6 previous months. VTE can be symptomatic or asymptomatic, can be located close to a central line, and of any type (DVT, PE, SVT)

Exclusion criteria

  • Patient already included in a trial studying antithrombotic therapy
  • Patient refusing the study
  • Patient under 18 and/or not competent to give informed consent

Treatment and study plan

VTE treatment in cancer patient description

Procedure

proportion of patients treated for evolutive VTE according to international recommendations

Primary outcomes

  1. Evaluation of the adherence to recommendations of VTE treatment in cancer patients

    Time frame: At baseline (J0)

    Proportion of patients treated for evolutive VTE according to international recommandations Patients could be hospitalised or could be out patient

Secondary outcomes

  1. Evaluation of VTE disease according to cancer diagnosis (proportion of SVT (Superficial Venous Thrombosis), DVT (Deep Venous Thrombosis), PE (Pulmonary Embolism)

    Time frame: At baseline (J0)

    Percentage of VTE (PE,DVT,SVT)and cancer type

  2. Proportion of asymptomatic VTE disease for this population

    Time frame: At baseline (J0)

    percentage of VTE and cancer status (local, metastatic)

  3. Feasibility of self injections for VTE treatment in cancer patients.

    Time frame: At baseline (J0)

    percentage of patients practising self injections

  4. Proportion of patients with catheter thrombosis

    Time frame: At baseline (J0)

    Percentage of patients receiving novel cancer therapies

Sponsors and collaborators

Lead sponsor

Floralis

Industry

Collaborators

  • Centre Hospitalier Universitaire, Amiens
  • Groupe Francophone Thrombose et Cancer (GFTC)
  • University Hospital, Grenoble

Registry information

Official study title

National Evaluation of the Adherence to Recommendations of VTE Treatment in Cancer Patients

Acronym: CARMEN

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Jun 1, 2011
Registry last updated
Mar 6, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.